January 5, 2018 / 1:19 PM / 9 months ago

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

Jan 5 (Reuters) - Xencor Inc:

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

* XENCOR INC - INITIATE PHASE 3 TRIAL IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below